Status:
WITHDRAWN
Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin
Lead Sponsor:
CPEX Pharmaceuticals Inc.
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if glucose peaks higher and earlier after a meal when a patient is given intranasal insulin instead of conventional insulin treatment.
Detailed Description
Diabetes mellitus is a common metabolic disorder characterized by hyperglycemia which when untreated is associated with microvascular disease. Most people with type 1 diabetes are treated with a combi...
Eligibility Criteria
Inclusion
- Diagnosis of Type 1 Diabetes
- Age 18-50
- Treatment management of MDI(multiple daily injections) or Insulin Pump
- BMI between 19-30 Kg/M2
- HbA1c less than or equal to 8.0%
- 75 g OGTT (oral glucose tolerance test)study with insulin concentrations \>80uU/mL
Exclusion
- Active Proliferative Retinopathy
- Active Nephropathy
- Chronic Upper Respiratory Conditions determined by MD
- Pregnant or Lactating Female
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00850161
Start Date
July 1 2009
End Date
September 1 2010
Last Update
February 15 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.